Ferdinand KC, et al. - In a high-risk, diverse, hypertensive population of 256 overweight or obese hypertensive individuals, researchers assessed firibastat for its efficacy and safety in lowering blood pressure (BP) levels. The investigators found that firibastat treatment resulted in a reduction of systolic automated office BP (AOBP) by 9.5 mmHg and diastolic AOBP by 4.2 mmHg. Reduction in systolic AOBP by 10.2 mmHg, 10.5 mmHg, and 8.9 mmHg was noted in obese patients, black patients, and non-black patients, respectively. Firibastat was found to be efficacious in lowering BP levels in a high-risk diverse group where monotherapy with angiotensin-I converting enzyme inhibitors or angiotensin-II receptor type 1 blockers may be less effective.